In Singapore, managing diabetes and achieving weight management often involves more than lifestyle changes alone. Medications such as Semaglutide, part of the GLP-1 receptor agonist (GLP-1 RA) class, play a role in regulating blood sugar and may assist with weight control.
Available under the brand names Rybelsus, Ozempic, and Wegovy, Semaglutide helps manage diabetes and obesity. Another related drug is Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss. These medications are part of an evolving approach to managing chronic conditions through a combination of pharmaceutical treatment and lifestyle modifications.
Semaglutide mimics the action of the incretin hormone produced in the intestines, regulating insulin release and lowering blood sugar after meals. Its formulations differ in their use:
This versatility allows Semaglutide to address the needs of individuals with type 2 diabetes, obesity, or both.
GLP-1 receptor agonists like Semaglutide (Rybelsus, Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) help manage diabetes and support weight loss through multiple mechanisms:
These combined effects make GLP-1 RAs a viable option for individuals requiring long-term support for chronic conditions.
GLP-1 RAs like Ozempic are used to lower HbA1c, which reflects average blood sugar levels over three months. In clinical trials, reductions of up to 1.8% in HbA1c have been observed after 40 weeks of use. Managing HbA1c levels helps reduce the risk of diabetes-related complications.
Wegovy and Tirzepatide have been linked to weight loss, with some individuals losing 15% to 20% of their body weight over 18 months. While Wegovy and Saxenda are specifically approved for weight management, Rybelsus and Ozempic also offer weight reduction as an additional benefit in individuals with diabetes.
Emerging studies suggest GLP-1 RAs may have positive effects on cardiovascular outcomes, such as reducing the risk of heart attacks or strokes. There is also evidence indicating potential benefits for kidney function, particularly in patients with diabetes.
Rybelsus is an oral form of Semaglutide, designed for patients who prefer non-injectable options. It is usually started with a 3 mg daily dose for the first month, followed by increases to 7 mg or 14 mg depending on individual requirements. To maximize absorption, it must be taken at least 30 minutes before the first meal of the day with water.
Ozempic is an injectable form of Semaglutide, typically used once per week for type 2 diabetes management. The initial dose starts at 0.25 mg weekly for four weeks, increasing to 0.5 mg per week. Depending on the patient’s needs, the dose can be adjusted to 1 mg or 2 mg per week to achieve optimal blood sugar control.
Wegovy is another injectable formulation of Semaglutide but is approved for weight management. It follows a gradual dosing schedule, starting at 0.25 mg per week and increasing every four weeks until the maintenance dose of 2.4 mg per week is reached.
Tirzepatide, another GLP-1 RA, functions similarly to Semaglutide but may interact with additional receptors, potentially offering unique benefits. While Mounjaro is used for diabetes management, Zepbound is available for weight loss.
In Singapore, several GLP-1 RAs are available:
Due to supply limitations, individuals seeking these medications may need to consult with their doctors regarding alternatives.
For optimal outcomes, these medications should be combined with lifestyle changes:
Some common side effects include:
While most side effects are mild and tend to improve over time, severe or persistent symptoms should be reported to a healthcare professional.
Studies suggest weight loss of approximately 10-15% of body weight over 12 months. Individual outcomes may vary.
Weight changes are often observed within the first month. More significant results typically emerge after three months of consistent use.
The medication is generally intended for long-term use. Discontinuation may result in weight regain, so ongoing lifestyle adjustments are recommended.
Weight regain is possible after stopping the medication. Maintaining a balanced diet and regular physical activity can help sustain weight loss progress.
Injections are generally well-tolerated, with only mild discomfort at the injection site reported by some individuals.
Some studies indicate that GLP-1 RAs may help reduce visceral fat, though individual responses may differ.
Semaglutide is not recommended during pregnancy or breastfeeding. Patients planning to conceive should consult with their healthcare provider about alternative treatments.
Copyrights 2023 by Edwin Lim Medical Aesthetic Clinic Pte. Ltd.